CAPR

About Capricor Therapeutics Inc (CAPR) Stock

Capricor Therapeutics Inc (CAPR) closed the 2026-09-18 session at $9.06, down 3.82% versus the previous close (-0.36). The stock opened at $9.29 and traded between $8.96 and $9.36 during that session. Session trading volume was 3.3M shares. The volume-weighted average price (VWAP) is $9.08.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Inc has a market capitalization of $547.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CAPR is listed on the XNAS exchange. The company employs approximately 231 people. Capricor Therapeutics Inc is headquartered in SAN DIEGO, CA. The recorded listing date is 2002-06-20.

On this page you can find market CAPR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.